Department of Rheumatology and Immunology, Shantou Central Hospital, Shantou, Guangdong, China.
Department of Geriatric Medicine, Division of Rheumatology AOUC, University of Florence, Florence, Italy.
Clin Rheumatol. 2019 May;38(5):1433-1436. doi: 10.1007/s10067-019-04462-z. Epub 2019 Feb 11.
In the past decade, lung ultrasound (LUS) B-lines and serum Krebs von den Lungen-6 (KL-6) antigen have been recognized as biomarkers of the connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Robust data have demonstrated that B-lines total numbers and KL-6 levels are correlated with high-resolution computed tomography findings, pulmonary function test, and some clinical parameters in CTD-ILDs. However, limited data are available regarding the use of these two biomarkers to follow CTD-ILDs. Herein, we report a case with anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis-associated ILD, successfully treated with high-dose methylprednisolone, cyclophosphamide, intravenous immunoglobulin, pirfenidone, and followed using lung ultrasound and KL-6.
在过去十年中，肺部超声（LUS）B 线和血清 Krebs von den Lungen-6（KL-6）抗原已被认为是结缔组织病相关间质性肺疾病（CTD-ILD）的生物标志物。大量数据表明，B 线总数和 KL-6 水平与高分辨率计算机断层扫描结果、肺功能测试以及 CTD-ILD 的一些临床参数相关。然而，关于这两种生物标志物用于监测 CTD-ILD 的数据有限。在此，我们报告了一例抗黑色素瘤分化相关基因 5 抗体阳性的临床无肌病性皮肌炎相关间质性肺病，经大剂量甲基强的松龙、环磷酰胺、静脉注射免疫球蛋白、吡非尼酮治疗后成功，并用肺部超声和 KL-6 进行随访。
